About Us Services Careers FAQ Contact Us 0
Home Medical Devices Neuroendocrine Carcinoma Market Trend, Growth to 2022-2030
Neuroendocrine Carcinoma Market

Neuroendocrine Carcinoma Market Size, Share & Trends Analysis Report By Site (Gastrointestinal, Lung, Brain, Pancreatic), By Diagnostic Tools (Imaging, Biopsy, Serology), By Treatment Type (Somatostatin Analogs, Targeted Therapy, Chemotherapy), By End User (Hospitals, Clinics, Oncology Centers, Ambulatory Surgery Centers), By Stage (Localized, Regional, Distant), By Grade (Low, Intermediate, High) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2022-2030

Report Code: SRMD2678DR
Last Updated : December 23, 2024
Author : Debashree Bora
Starting From
USD 2300
Buy Now
File Formats

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Neuroendocrine Carcinoma Market Introduction
    2. By Site
      1. Introduction
        1. Site By Value
      2. Gastrointestinal
        1. By Value
      3. Lung
        1. By Value
      4. Brain
        1. By Value
      5. Pancreatic
        1. By Value
    3. By Diagnostic Tools
      1. Introduction
        1. Diagnostic Tools By Value
      2. Imaging
        1. By Value
      3. Biopsy
        1. By Value
      4. Serology
        1. By Value
    4. By Treatment Type
      1. Introduction
        1. Treatment Type By Value
      2. Somatostatin Analogs
        1. By Value
      3. Targeted Therapy
        1. By Value
        2. Tyrosine Kinase Inhibitors
          1. Tyrosine Kinase Inhibitors By Value
        3. mTOR Inhibitors
          1. mTOR Inhibitors By Value
      4. Chemotherapy
        1. By Value
        2. Antimetabolites
          1. Antimetabolites By Value
        3. Alkylating Agents
          1. Alkylating Agents By Value
        4. Natural Products
          1. Natural Products By Value
    5. By End User
      1. Introduction
        1. End User By Value
      2. Hospitals
        1. By Value
      3. Clinics
        1. By Value
      4. Oncology Centers
        1. By Value
      5. Ambulatory Surgery Centers
        1. By Value
    6. By Stage
      1. Introduction
        1. Stage By Value
      2. Localized
        1. By Value
      3. Regional
        1. By Value
      4. Distant
        1. By Value
    7. By Grade
      1. Introduction
        1. Grade By Value
      2. Low
        1. By Value
      3. Intermediate
        1. By Value
      4. High
        1. By Value
    1. Introduction
    2. By Site
      1. Introduction
        1. Site By Value
      2. Gastrointestinal
        1. By Value
      3. Lung
        1. By Value
      4. Brain
        1. By Value
      5. Pancreatic
        1. By Value
    3. By Diagnostic Tools
      1. Introduction
        1. Diagnostic Tools By Value
      2. Imaging
        1. By Value
      3. Biopsy
        1. By Value
      4. Serology
        1. By Value
    4. By Treatment Type
      1. Introduction
        1. Treatment Type By Value
      2. Somatostatin Analogs
        1. By Value
      3. Targeted Therapy
        1. By Value
        2. Tyrosine Kinase Inhibitors
          1. Tyrosine Kinase Inhibitors By Value
        3. mTOR Inhibitors
          1. mTOR Inhibitors By Value
      4. Chemotherapy
        1. By Value
        2. Antimetabolites
          1. Antimetabolites By Value
        3. Alkylating Agents
          1. Alkylating Agents By Value
        4. Natural Products
          1. Natural Products By Value
    5. By End User
      1. Introduction
        1. End User By Value
      2. Hospitals
        1. By Value
      3. Clinics
        1. By Value
      4. Oncology Centers
        1. By Value
      5. Ambulatory Surgery Centers
        1. By Value
    6. By Stage
      1. Introduction
        1. Stage By Value
      2. Localized
        1. By Value
      3. Regional
        1. By Value
      4. Distant
        1. By Value
    7. By Grade
      1. Introduction
        1. Grade By Value
      2. Low
        1. By Value
      3. Intermediate
        1. By Value
      4. High
        1. By Value
    8. U.S.
      1. By Site
        1. Introduction
          1. Site By Value
        2. Gastrointestinal
          1. By Value
        3. Lung
          1. By Value
        4. Brain
          1. By Value
        5. Pancreatic
          1. By Value
      2. By Diagnostic Tools
        1. Introduction
          1. Diagnostic Tools By Value
        2. Imaging
          1. By Value
        3. Biopsy
          1. By Value
        4. Serology
          1. By Value
      3. By Treatment Type
        1. Introduction
          1. Treatment Type By Value
        2. Somatostatin Analogs
          1. By Value
        3. Targeted Therapy
          1. By Value
          2. Tyrosine Kinase Inhibitors
            1. Tyrosine Kinase Inhibitors By Value
          3. mTOR Inhibitors
            1. mTOR Inhibitors By Value
        4. Chemotherapy
          1. By Value
          2. Antimetabolites
            1. Antimetabolites By Value
          3. Alkylating Agents
            1. Alkylating Agents By Value
          4. Natural Products
            1. Natural Products By Value
      4. By End User
        1. Introduction
          1. End User By Value
        2. Hospitals
          1. By Value
        3. Clinics
          1. By Value
        4. Oncology Centers
          1. By Value
        5. Ambulatory Surgery Centers
          1. By Value
      5. By Stage
        1. Introduction
          1. Stage By Value
        2. Localized
          1. By Value
        3. Regional
          1. By Value
        4. Distant
          1. By Value
      6. By Grade
        1. Introduction
          1. Grade By Value
        2. Low
          1. By Value
        3. Intermediate
          1. By Value
        4. High
          1. By Value
    9. Canada
    1. Introduction
    2. By Site
      1. Introduction
        1. Site By Value
      2. Gastrointestinal
        1. By Value
      3. Lung
        1. By Value
      4. Brain
        1. By Value
      5. Pancreatic
        1. By Value
    3. By Diagnostic Tools
      1. Introduction
        1. Diagnostic Tools By Value
      2. Imaging
        1. By Value
      3. Biopsy
        1. By Value
      4. Serology
        1. By Value
    4. By Treatment Type
      1. Introduction
        1. Treatment Type By Value
      2. Somatostatin Analogs
        1. By Value
      3. Targeted Therapy
        1. By Value
        2. Tyrosine Kinase Inhibitors
          1. Tyrosine Kinase Inhibitors By Value
        3. mTOR Inhibitors
          1. mTOR Inhibitors By Value
      4. Chemotherapy
        1. By Value
        2. Antimetabolites
          1. Antimetabolites By Value
        3. Alkylating Agents
          1. Alkylating Agents By Value
        4. Natural Products
          1. Natural Products By Value
    5. By End User
      1. Introduction
        1. End User By Value
      2. Hospitals
        1. By Value
      3. Clinics
        1. By Value
      4. Oncology Centers
        1. By Value
      5. Ambulatory Surgery Centers
        1. By Value
    6. By Stage
      1. Introduction
        1. Stage By Value
      2. Localized
        1. By Value
      3. Regional
        1. By Value
      4. Distant
        1. By Value
    7. By Grade
      1. Introduction
        1. Grade By Value
      2. Low
        1. By Value
      3. Intermediate
        1. By Value
      4. High
        1. By Value
    8. U.K.
      1. By Site
        1. Introduction
          1. Site By Value
        2. Gastrointestinal
          1. By Value
        3. Lung
          1. By Value
        4. Brain
          1. By Value
        5. Pancreatic
          1. By Value
      2. By Diagnostic Tools
        1. Introduction
          1. Diagnostic Tools By Value
        2. Imaging
          1. By Value
        3. Biopsy
          1. By Value
        4. Serology
          1. By Value
      3. By Treatment Type
        1. Introduction
          1. Treatment Type By Value
        2. Somatostatin Analogs
          1. By Value
        3. Targeted Therapy
          1. By Value
          2. Tyrosine Kinase Inhibitors
            1. Tyrosine Kinase Inhibitors By Value
          3. mTOR Inhibitors
            1. mTOR Inhibitors By Value
        4. Chemotherapy
          1. By Value
          2. Antimetabolites
            1. Antimetabolites By Value
          3. Alkylating Agents
            1. Alkylating Agents By Value
          4. Natural Products
            1. Natural Products By Value
      4. By End User
        1. Introduction
          1. End User By Value
        2. Hospitals
          1. By Value
        3. Clinics
          1. By Value
        4. Oncology Centers
          1. By Value
        5. Ambulatory Surgery Centers
          1. By Value
      5. By Stage
        1. Introduction
          1. Stage By Value
        2. Localized
          1. By Value
        3. Regional
          1. By Value
        4. Distant
          1. By Value
      6. By Grade
        1. Introduction
          1. Grade By Value
        2. Low
          1. By Value
        3. Intermediate
          1. By Value
        4. High
          1. By Value
    9. Germany
    10. France
    11. Spain
    12. Italy
    13. Russia
    14. Nordic
    15. Benelux
    16. Rest of Europe
    1. Introduction
    2. By Site
      1. Introduction
        1. Site By Value
      2. Gastrointestinal
        1. By Value
      3. Lung
        1. By Value
      4. Brain
        1. By Value
      5. Pancreatic
        1. By Value
    3. By Diagnostic Tools
      1. Introduction
        1. Diagnostic Tools By Value
      2. Imaging
        1. By Value
      3. Biopsy
        1. By Value
      4. Serology
        1. By Value
    4. By Treatment Type
      1. Introduction
        1. Treatment Type By Value
      2. Somatostatin Analogs
        1. By Value
      3. Targeted Therapy
        1. By Value
        2. Tyrosine Kinase Inhibitors
          1. Tyrosine Kinase Inhibitors By Value
        3. mTOR Inhibitors
          1. mTOR Inhibitors By Value
      4. Chemotherapy
        1. By Value
        2. Antimetabolites
          1. Antimetabolites By Value
        3. Alkylating Agents
          1. Alkylating Agents By Value
        4. Natural Products
          1. Natural Products By Value
    5. By End User
      1. Introduction
        1. End User By Value
      2. Hospitals
        1. By Value
      3. Clinics
        1. By Value
      4. Oncology Centers
        1. By Value
      5. Ambulatory Surgery Centers
        1. By Value
    6. By Stage
      1. Introduction
        1. Stage By Value
      2. Localized
        1. By Value
      3. Regional
        1. By Value
      4. Distant
        1. By Value
    7. By Grade
      1. Introduction
        1. Grade By Value
      2. Low
        1. By Value
      3. Intermediate
        1. By Value
      4. High
        1. By Value
    8. China
      1. By Site
        1. Introduction
          1. Site By Value
        2. Gastrointestinal
          1. By Value
        3. Lung
          1. By Value
        4. Brain
          1. By Value
        5. Pancreatic
          1. By Value
      2. By Diagnostic Tools
        1. Introduction
          1. Diagnostic Tools By Value
        2. Imaging
          1. By Value
        3. Biopsy
          1. By Value
        4. Serology
          1. By Value
      3. By Treatment Type
        1. Introduction
          1. Treatment Type By Value
        2. Somatostatin Analogs
          1. By Value
        3. Targeted Therapy
          1. By Value
          2. Tyrosine Kinase Inhibitors
            1. Tyrosine Kinase Inhibitors By Value
          3. mTOR Inhibitors
            1. mTOR Inhibitors By Value
        4. Chemotherapy
          1. By Value
          2. Antimetabolites
            1. Antimetabolites By Value
          3. Alkylating Agents
            1. Alkylating Agents By Value
          4. Natural Products
            1. Natural Products By Value
      4. By End User
        1. Introduction
          1. End User By Value
        2. Hospitals
          1. By Value
        3. Clinics
          1. By Value
        4. Oncology Centers
          1. By Value
        5. Ambulatory Surgery Centers
          1. By Value
      5. By Stage
        1. Introduction
          1. Stage By Value
        2. Localized
          1. By Value
        3. Regional
          1. By Value
        4. Distant
          1. By Value
      6. By Grade
        1. Introduction
          1. Grade By Value
        2. Low
          1. By Value
        3. Intermediate
          1. By Value
        4. High
          1. By Value
    9. Korea
    10. Japan
    11. India
    12. Australia
    13. Taiwan
    14. South East Asia
    15. Rest of Asia-Pacific
    1. Introduction
    2. By Site
      1. Introduction
        1. Site By Value
      2. Gastrointestinal
        1. By Value
      3. Lung
        1. By Value
      4. Brain
        1. By Value
      5. Pancreatic
        1. By Value
    3. By Diagnostic Tools
      1. Introduction
        1. Diagnostic Tools By Value
      2. Imaging
        1. By Value
      3. Biopsy
        1. By Value
      4. Serology
        1. By Value
    4. By Treatment Type
      1. Introduction
        1. Treatment Type By Value
      2. Somatostatin Analogs
        1. By Value
      3. Targeted Therapy
        1. By Value
        2. Tyrosine Kinase Inhibitors
          1. Tyrosine Kinase Inhibitors By Value
        3. mTOR Inhibitors
          1. mTOR Inhibitors By Value
      4. Chemotherapy
        1. By Value
        2. Antimetabolites
          1. Antimetabolites By Value
        3. Alkylating Agents
          1. Alkylating Agents By Value
        4. Natural Products
          1. Natural Products By Value
    5. By End User
      1. Introduction
        1. End User By Value
      2. Hospitals
        1. By Value
      3. Clinics
        1. By Value
      4. Oncology Centers
        1. By Value
      5. Ambulatory Surgery Centers
        1. By Value
    6. By Stage
      1. Introduction
        1. Stage By Value
      2. Localized
        1. By Value
      3. Regional
        1. By Value
      4. Distant
        1. By Value
    7. By Grade
      1. Introduction
        1. Grade By Value
      2. Low
        1. By Value
      3. Intermediate
        1. By Value
      4. High
        1. By Value
    8. UAE
      1. By Site
        1. Introduction
          1. Site By Value
        2. Gastrointestinal
          1. By Value
        3. Lung
          1. By Value
        4. Brain
          1. By Value
        5. Pancreatic
          1. By Value
      2. By Diagnostic Tools
        1. Introduction
          1. Diagnostic Tools By Value
        2. Imaging
          1. By Value
        3. Biopsy
          1. By Value
        4. Serology
          1. By Value
      3. By Treatment Type
        1. Introduction
          1. Treatment Type By Value
        2. Somatostatin Analogs
          1. By Value
        3. Targeted Therapy
          1. By Value
          2. Tyrosine Kinase Inhibitors
            1. Tyrosine Kinase Inhibitors By Value
          3. mTOR Inhibitors
            1. mTOR Inhibitors By Value
        4. Chemotherapy
          1. By Value
          2. Antimetabolites
            1. Antimetabolites By Value
          3. Alkylating Agents
            1. Alkylating Agents By Value
          4. Natural Products
            1. Natural Products By Value
      4. By End User
        1. Introduction
          1. End User By Value
        2. Hospitals
          1. By Value
        3. Clinics
          1. By Value
        4. Oncology Centers
          1. By Value
        5. Ambulatory Surgery Centers
          1. By Value
      5. By Stage
        1. Introduction
          1. Stage By Value
        2. Localized
          1. By Value
        3. Regional
          1. By Value
        4. Distant
          1. By Value
      6. By Grade
        1. Introduction
          1. Grade By Value
        2. Low
          1. By Value
        3. Intermediate
          1. By Value
        4. High
          1. By Value
    9. Turkey
    10. Saudi Arabia
    11. South Africa
    12. Egypt
    13. Nigeria
    14. Rest of MEA
    1. Introduction
    2. By Site
      1. Introduction
        1. Site By Value
      2. Gastrointestinal
        1. By Value
      3. Lung
        1. By Value
      4. Brain
        1. By Value
      5. Pancreatic
        1. By Value
    3. By Diagnostic Tools
      1. Introduction
        1. Diagnostic Tools By Value
      2. Imaging
        1. By Value
      3. Biopsy
        1. By Value
      4. Serology
        1. By Value
    4. By Treatment Type
      1. Introduction
        1. Treatment Type By Value
      2. Somatostatin Analogs
        1. By Value
      3. Targeted Therapy
        1. By Value
        2. Tyrosine Kinase Inhibitors
          1. Tyrosine Kinase Inhibitors By Value
        3. mTOR Inhibitors
          1. mTOR Inhibitors By Value
      4. Chemotherapy
        1. By Value
        2. Antimetabolites
          1. Antimetabolites By Value
        3. Alkylating Agents
          1. Alkylating Agents By Value
        4. Natural Products
          1. Natural Products By Value
    5. By End User
      1. Introduction
        1. End User By Value
      2. Hospitals
        1. By Value
      3. Clinics
        1. By Value
      4. Oncology Centers
        1. By Value
      5. Ambulatory Surgery Centers
        1. By Value
    6. By Stage
      1. Introduction
        1. Stage By Value
      2. Localized
        1. By Value
      3. Regional
        1. By Value
      4. Distant
        1. By Value
    7. By Grade
      1. Introduction
        1. Grade By Value
      2. Low
        1. By Value
      3. Intermediate
        1. By Value
      4. High
        1. By Value
    8. Brazil
      1. By Site
        1. Introduction
          1. Site By Value
        2. Gastrointestinal
          1. By Value
        3. Lung
          1. By Value
        4. Brain
          1. By Value
        5. Pancreatic
          1. By Value
      2. By Diagnostic Tools
        1. Introduction
          1. Diagnostic Tools By Value
        2. Imaging
          1. By Value
        3. Biopsy
          1. By Value
        4. Serology
          1. By Value
      3. By Treatment Type
        1. Introduction
          1. Treatment Type By Value
        2. Somatostatin Analogs
          1. By Value
        3. Targeted Therapy
          1. By Value
          2. Tyrosine Kinase Inhibitors
            1. Tyrosine Kinase Inhibitors By Value
          3. mTOR Inhibitors
            1. mTOR Inhibitors By Value
        4. Chemotherapy
          1. By Value
          2. Antimetabolites
            1. Antimetabolites By Value
          3. Alkylating Agents
            1. Alkylating Agents By Value
          4. Natural Products
            1. Natural Products By Value
      4. By End User
        1. Introduction
          1. End User By Value
        2. Hospitals
          1. By Value
        3. Clinics
          1. By Value
        4. Oncology Centers
          1. By Value
        5. Ambulatory Surgery Centers
          1. By Value
      5. By Stage
        1. Introduction
          1. Stage By Value
        2. Localized
          1. By Value
        3. Regional
          1. By Value
        4. Distant
          1. By Value
      6. By Grade
        1. Introduction
          1. Grade By Value
        2. Low
          1. By Value
        3. Intermediate
          1. By Value
        4. High
          1. By Value
    9. Mexico
    10. Argentina
    11. Chile
    12. Colombia
    13. Rest of LATAM
    1. Neuroendocrine Carcinoma Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. Novartis AG
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Amgen Inc.
    3. Boehringer Ingelheim GmbH
    4. Dauntless Pharmaceuticals
    5. Hutchison MediPharma Limited
    6. AVEO Pharmaceuticals Inc
    7. Chiasma Inc.
    8. Aegis Therapeutics
    9. Ispen
    10. Progenics Pharmaceuticals Inc.
    11. Tarveda Therapeutics
    12. Pfizer
    13. Jubilant Life Sciences Ltd. (Jubilant DraxImage)
    14. AbbV
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer

Related Reports

Global Report
Bispecific Antibodies Market Size The global bispecific antibodies market size was valued at USD 11.84 billion in 2024 and is expected to grow from USD 17.10 billion in 2025 to USD 323.21 billion by 2033, growing at a CAGR of 44.4% du
Buy Now
Global Report
The global X-Ray Inspection System Market size was valued at USD 734.5 Million in 2022 and is projected to reach USD 1231.3 Million by 2031, registering a CAGR of 6.6% during the forecast period (2023-2031). The rising awareness of the bene
Buy Now
Global Report
Inflight Catering Market Size and Trends The global inflight catering market size was valued at USD 13.62 billion in 2023. It is projected to reach from USD 15.16 billion in 2024 to USD 35.75 billion by 2032, growing at a CAGR of 11.32% during the f
Buy Now
Global Report
Bladder Scanners Market Size The global bladder scanners market size was valued at USD 149.28 million in 2024 and is projected to grow from USD 162.36 million in 2025 to reach USD 270.46 million by 2033, exhibiting a CA
Buy Now
Global Report
Hair Removal Wax Market Size The global hair removal wax market size was valued at USD 14426.26 million in 2024 and is projected to reach from USD 15133.14 million in 2025 to USD 22188.76 million by 2033, growing at a CAGR of 4.9% during t
Buy Now

Purchase Benefits

  • Eligible for a free updated report next year
  • Completely customizable scope
  • 30% discount on your next purchase
  • Dedicated account manager
  • Query resolution within 24 hours
  • Permission to print the report

We are featured on :

www.straitsresearch.com
© Copyright 2025. All rights Reserved.